Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Panel Expert
2.2. Selection of the Delphi Domains and Items
2.3. Statistical Analysis
3. Results
3.1. Structured Report RC Staging
- In the “Exam technique” section: scanner field strength and renal function;
- In the “Report” section: primary tumor visible on imaging, location and positive lymph nodes with extracapsular extension.
3.2. Structured Report RC Restaging
- In the “Report” section: MRI Tumor Regression Grade (TRG) according to Dworak, Residual mass diffusion-weighted imaging (DWI) appearance, Mucin Response, and a healthy rectal wall appearance.
3.3. Consensus Agreement
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Appendix A.1. Patient Clinical Data
FIELD | DETAIL | NOTES/ALLOWED VALUES | |
ANTHROPOMETRIC DATA | |||
Weight | Numeric [Kg] | ||
Height | Numeric [cm] | ||
BMI | Numeric [calculated automatically] | ||
BSA | Numeric [calculated automatically] | ||
Age | Numeric | ||
age class |
| ||
PERSONAL RATINGS | |||
Family History for colorectal cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Family History for cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Personal background for other malignancies | Yes/No | ||
Notes | |||
Hereditary genetic alterations (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Predisposing pathologies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Risk factors (detail visible only if “Yes” and repeatable) | Smoker | Yes/No | |
SMOKING DETAILS (visible only if indicated Smoker = yes) | |||
Smoker (visible only if indicated Smoker) |
| ||
Cigarette smoking | Yes/No | ||
Number of cigarettes per day [if current smoker] |
| ||
Years of smoking | Numeric | ||
Number of years of cessation [if ex-smoker] |
| ||
Packs/year [if ex-smoker or current smoker] | Numeric [calculated automatically] (No. of cigarettes per day × smoke years/20) | ||
Electronic cigarette | Yes/No | ||
Number of refills per day [if electronic cigarette = yes] | Numeric | ||
Number of years [if electronic cigarette = yes] | Numeric | ||
Notes | |||
High alcohol intake | Yes (more than 1 glass per day, if female more than a 2 glasses per day, if male) No | ||
High meat intake | Yes (eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola]) No | ||
High intake of salami | Yes (eats cured meats more than once a week [salami, mortadella, sausage, frankfurters …]) No | ||
Poor vegetable intake | Yes (less than 2 times per day) No (1 serving is considered as a salad plate [at least 50 g] or half a plate of cooked/raw vegetables or a glass of juice/centrifuge) | ||
Poor fruit intake | Yes (less than 3 whole fruits per day) No (1 whole fruit, such as apple, pear or orange, or 2/3 small fruits, such as apricots plums or fruit salad bowl) | ||
Notes | |||
Microsatellite instability | Yes/No | ||
Notes | |||
ALLERGIES AND ADVERSE REACTIONS | |||
Allergies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Active substance/molecule [if drug or MDC allergy] | |||
Commercial name [if drug or MDC allergy] | |||
Notes | |||
PREVIOUS adverse reactions (detail visible only if “Yes” and repeatable) | Yes/No | ||
Date | Month/year [mm/yyyy] | ||
Description | |||
Grade |
| ||
Timing |
| ||
Notes |
Appendix A.2. Clinical Evaluation
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Clinical Data | ||
Previous examination (detail visible only if “Yes” and repeatable) | Yes/No | |
Type |
| |
Date | ||
Notes | ||
Rectal exploration performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Trans-rectal ultrasound performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Histological examination of biopsy | Yes/No | |
Notes | ||
CEA dosage | Numeric | |
Blood exam completed | Numeric | |
Creatinine | Numeric | |
Liver function |
|
Appendix A.3. Exam Technique
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Examination Data | ||
Examination date | ||
Clinical indication | Post neoadjuvant treatment | |
Sequences |
| |
MDC | ||
MDC (detail visible only if “Yes”) | Yes/No | |
Active principle | ||
Commercial name | ||
Dosage | Numeric [mL] | |
Flow rate | Numeric [mL/s] | |
Concentration | Numeric [mg I/mL] | |
Notes | ||
Premedication for allergy | Yes/No | |
Notes | ||
Preventive hydration for kidney failure | Yes/No | |
Notes | ||
Creatinine | ||
GFR (Glomerular Filtration Rate) | Numeric [mL/min] GFR = 141 × min (serum creatinine/kappa, 1) alpha × max (serum creatinine/kappa, 1) − 1.209 × 0.993Age × Gender × Race https://www.merckmanuals.com/medical-calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021 | |
ADVERSE EVENTS | ||
Ongoing adverse events (detail visible only if “Yes”) | Yes/No | |
Date and event time | ||
Grade |
| |
Timing |
| |
Type | ALLERGIC/ALLERGIC-LIKE mild
Mild
| |
Treatment type |
| |
Event resolution |
| |
Notes |
Appendix A.4. Report
FIELD | DETAIL | NOTES/ALLOWED VALUES | |||
Tumor Staging | |||||
Position | Type |
| |||
Notes | |||||
Distance from the inferior border of the tumor to the anal verge | Numeric [cm] | ||||
Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm] | ||||
Craniocaudal tumor length | Yes/No | Numeric [cm] | |||
Morphology | Type |
| |||
Notes | |||||
Localization | Type |
| |||
Local invasion | Type |
| |||
Anal sphincter complex involvement (detail visible only if “Yes”) | Notes | ||||
Sphincter invasion thickness |
| ||||
Height sphincter invasion |
| ||||
CRM Involvement | |||||
The shortest distance between the outermost part of the rectal tumor and the MRF | Numeric [mm] | ||||
Margins | Type (multiple choice) |
| |||
Minimum distance localization | Type |
| |||
Type | |||||
Relationship with anterior peritoneal reflection | Type |
| |||
LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESOCT ADIPOSE TISSUE | |||||
Lymph node metastases (detail visible only if “Yes”) | Yes/No | ||||
Type |
| ||||
Morphology |
| ||||
Notes | |||||
Tumor deposits into mesorectal space (detail visible only if “Yes”) | Notes | ||||
Yes/No | |||||
Numeric | |||||
Extramural vascular invasion | Notes | ||||
Yes/No | |||||
CONCLUSION | |||||
Diagnosis | cT, N, M, Stage (TNM classification, 8th Edition, AJCC-UICC 2017) | Tx T0 Tis T1 T2 T3 T4 | Diagnosis | cT, N, M, Stage (TNM, 8th Edition classification, AJCC-UICC 2017) | Tx T0 Tis T1 T2 T3 T4 |
Annotations and comments |
Appendix A.5. Images
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Significant key images | Images |
Appendix B
Appendix B.1. Patient Clinical Data
FIELD | DETAIL | NOTES/ALLOWED VALUES | |
ANTHROPOMETRIC DATA | |||
Weight | Numeric [Kg] | ||
Height | Numeric [cm] | ||
BMI | Numeric [calculated automatically] | ||
BSA | Numeric [calculated automatically] | ||
Age | Numeric | ||
age class |
| ||
PERSONAL RATINGS | |||
Family History for colorectal cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Family History for cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Personal background for other malignancies | Yes/No | ||
Notes | |||
Hereditary genetic alterations (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Predisposing pathologies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Risk factors (detail visible only if “Yes” and repeatable) | Smoker | Yes/No | |
SMOKER DETAILS (visible only if indicated Smoker = yes) | |||
Smoker (visible only if indicated Smoker) |
| ||
Cigarette smoking | Yes/No | ||
Number of cigarettes per day [if current smoker] |
| ||
Years of smoke | Numeric | ||
Number of years of cessation [if ex-smoker] |
| ||
Packs/year [if ex-smoker or current smoker] | Numeric [calculated automatically] (No. of cigarettes per day × smoke years/20) | ||
Electronic cigarette | Yes/No | ||
Number of refills per day [if electronic cigarette = yes] | Numeric | ||
Number of years [if electronic cigarette = yes] | Numeric | ||
Notes | |||
High alcohol intake | Yes (more than 1 glass per day, if female, more than a 2 glasses per day, if male) No | ||
High meat intake | Yes (eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola]) No | ||
High intake of salami | Yes (eats cured meats more than once a week [salami, mortadella, sausage, frankfurters …]) No | ||
Poor vegetable intake | Yes (less than 2 times per day) No (1 serving is considered as a salad plate [at least 50 g] or half a plate of cooked/raw vegetables or a glass of juice/centrifuge) | ||
Poor fruit intake | Yes (less than 3 whole fruits per day) No (1 whole fruit, such as apple, pear or orange, or 2/3 small fruits, such as apricots plums or fruit salad bowl) | ||
Notes | |||
Microsatellite instability | Yes/No | ||
Notes | |||
ALLERGIES AND ADVERSE REACTIONS | |||
Allergies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Active substance/molecule [if drug or MDC allergy] | |||
Commercial name [if drug or MDC allergy] | |||
Notes | |||
PREVIOUS adverse reactions (detail visible only if “Yes” and repeatable) | Yes/No | ||
Date | Month/year [mm/yyyy] | ||
Description | |||
Grade |
| ||
Timing |
| ||
Notes |
Appendix B.2. Clinical Evaluation
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Clinical Data | ||
Previous examination (detail visible only if “Yes” and repeatable) | Yes/No | |
Type |
| |
Date | ||
Notes | ||
Rectal exploration performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Trans-rectal ultrasound performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Histological examination of biopsy | Yes/No | |
Notes | ||
CEA dosage | Numeric | |
Blood exam completed | Numeric | |
Creatinine | Numeric | |
Liver function |
|
Appendix B.3. Exam Technique
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Examination Data | ||
Examination date | ||
Clinical indication | Post neoadjuvant treatment | |
Sequences |
| |
MDC | ||
MDC (detail visible only if “Yes”) | Yes/No | |
Active principle | ||
Commercial name | ||
Dosage | Numeric [mL] | |
Flow rate | Numeric [mL/s] | |
Concentration | Numeric [mg I/mL] | |
Notes | ||
Premedication for allergy | Yes/No | |
Notes | ||
Preventive hydration for kidney failure | Yes/No | |
Notes | ||
Creatinine | ||
GFR (Glomerular Filtration Rate) | Numeric [mL/min] GFR = 141 × min (serum creatinine/kappa, 1) alpha × max (serum creatinine/kappa, 1) − 1.209 × 0.993Age × Gender × Race https://www.merckmanuals.com/medical-calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021 | |
ADVERSE EVENTS | ||
Ongoing adverse events (detail visible only if “Yes”) | Yes/No | |
Date and event time | ||
Grade |
| |
Timing |
| |
Type | ALLERGIC/ALLERGIC-LIKE mild
Mild
| |
Treatment type |
| |
Event resolution |
| |
Notes |
Appendix B.4. Report
FIELD | DETAIL | NOTES/ALLOWED VALUES | |||
Tumor Staging | |||||
Remaining tumor |
| ||||
Notes | |||||
yT-stage |
| ||||
Notes | |||||
Distance from the inferior border of the tumor to the anal verge | Numeric [cm] | ||||
Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm] | ||||
Craniocaudal tumor lenght | Numeric [cm] | ||||
Anal sphincter complex involvement (detail visible only if “Yes”) | Yes/No | ||||
Type (multiple choice) |
| ||||
Localization |
| ||||
CRM Involvement | |||||
The shortest distance between the outermost part of the rectal tumor and the MRF | Numeric [mm] | ||||
Margins |
| ||||
Localitation | Type (multiple choice) |
| |||
O-clock position | |||||
Relationship with anterior peritoneal reflection | Type |
| |||
LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESOCT ADIPOSE TISSUE | |||||
Lymph node metastases (detail visible only if “Yes”) | Yes/No | ||||
Type |
| ||||
Number of suspected residual mesorectal lymph nodes (≥5 mm) | Numeric | ||||
Number of suspected extra mesorectal lymph nodes (≥5 mm) | Numeric | ||||
Tumor deposits into mesorectal space (detail visible only if “Yes”) | Notes | ||||
Yes/No | |||||
Numeric | |||||
Extramural vascular invasion | Notes | ||||
Yes/No | |||||
CONCLUSION | |||||
Diagnosis | cT, N, M, Stage (TNM classification, 8th Edition, AJCC-UICC 2017) | TX T0 Tis T1 T2 T3 T4 | NX N0 N1 N1a N1b N1c | MX M0 M1 | Stage 0 Stage I Stage IIa Stage IIb Stage IIIa Stage IIIb Stage IIIc Stage IV |
Annotations and comments |
Appendix B.5. Images
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Significant key images | Images |
Appendix C
Appendix C.1. Patient Clinical Data
FIELD | DETAIL | NOTES/ALLOWED VALUES | |
ANTHROPOMETRIC DATA | |||
Weight | Numeric [Kg] | ||
Height | Numeric [cm] | ||
BMI | Numeric [calculated automatically] | ||
BSA | Numeric [calculated automatically] | ||
Age | Numeric | ||
age class |
| ||
PERSONAL RATINGS | |||
Family History for colorectal cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Family History for cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Personal background for other malignancies | Yes/No | ||
Notes | |||
Hereditary genetic alterations (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Predisposing pathologies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Risk factors (detail visible only if “Yes” and repeatable) | Smoker | Yes/No | |
SMOKER DETAILS (visible only if indicated Smoker = yes) | |||
Smoker (visible only if indicated Smoker) |
| ||
Cigarette smoking | Yes/No | ||
Number of cigarettes per day [if current smoker] |
| ||
Years of smoke | Numeric | ||
Number of years of cessation [if ex-smoker] |
| ||
Packs/year [if ex-smoker or current smoker] | Numeric [calculated automatically] (No. of cigarettes per day × smoke years/20) | ||
Electronic cigarette | Yes/No | ||
Number of refills per day [if electronic cigarette = yes] | Numeric | ||
Number of years [if electronic cigarette = yes] | Numeric | ||
Notes | |||
High alcohol intake | Yes (more than 1 glass per day, if female, more than a 2 glasses per day, if male) No | ||
High meat intake | Yes (eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola]) No | ||
High intake of salami | Yes (eats cured meats more than once a week [salami, mortadella, sausage, frankfurters …]) No | ||
Poor vegetable intake | Yes (less than 2 times per day) No (1 serving is considered as a salad plate [at least 50 g] or half a plate of cooked/raw vegetables or a glass of juice/centrifuge) | ||
Poor fruit intake | Yes (less than 3 whole fruits per day) No (1 whole fruit, such as apple, pear or orange, or 2/3 small fruits, such as apricots plums or fruit salad bowl) | ||
Notes | |||
Microsatellite instability | Yes/No | ||
Notes | |||
ALLERGIES AND ADVERSE REACTIONS | |||
Allergies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Active substance/molecule [if drug or MDC allergy] | |||
Commercial name [if drug or MDC allergy] | |||
Notes | |||
PREVIOUS adverse reactions (detail visible only if “Yes” and repeatable) | Yes/No | ||
Date | Month/year [mm/yyyy] | ||
Description | |||
Grade |
| ||
Timing |
| ||
Notes |
Appendix C.2. Clinical Evaluation
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Clinical Data | ||
Previous examination (detail visible only if “Yes” and repeatable) | Yes/No | |
Type |
| |
Date | ||
Notes | ||
Rectal exploration performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Trans-rectal ultrasound performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Histological examination of biopsy | Yes/No | Histotype (visible only if indicated Histologic examination of biopsy = yes) |
Notes | ||
CEA dosage | Numeric | |
Blood exam completed | Numeric | |
Creatinine | Numeric | |
Liver function |
|
Appendix C.3. Exam Technique
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Examination Data | ||
Examination date | ||
Clinical indication | Post neoadjuvant treatment | |
Scanner field strength | 1.5T/3T | |
Sequences (detail visible only if DWI is selected) |
| |
b-value | Numeric [s/mm2] | |
MDC | ||
MDC (detail visible only if “Yes”) | Yes/No | |
Molecule | ||
Commercial name | ||
Volume | Numeric [mL] | |
Flow rate | Numeric [mL/s] | |
Concentration | Numeric [mg I/mL] | |
Notes | ||
Premedication for allergy | Yes/No | |
Notes | ||
Renal function | Creatinine | Numeric [mg/dL] |
GFR (Glomerular Filtration Rate) | Numeric [mL/min] GFR = 141 × min (serum creatinine/kappa, 1) alpha × max (serum creatinine/kappa, 1) − 1.209 × 0.993Age × Gender × Race https://www.merckmanuals.com/medical-calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021 | |
Preventive hydration | Yes/No | |
Notes | ||
ADVERSE EVENTS | ||
Ongoing adverse events (detail visible only if “Yes”) | Yes/No | |
Date and event time | ||
Grade |
| |
Timing |
| |
Type | ALLERGIC/ALLERGIC-LIKE mild
Mild
| |
Treatment type |
| |
Event resolution |
| |
Notes |
Appendix C.4. Report
FIELD | DETAIL | NOTES/ALLOWED VALUES | |||
Tumor Staging | |||||
Primary tumor visible on imaging | Yes/No | ||||
Position | Type |
| |||
Notes | |||||
Distance from the inferior border of the tumor to the anal verge | Numeric [cm] | ||||
Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm] | ||||
Craniocaudal tumor length | Numeric [cm] | ||||
Morphology | Type |
| |||
Notes | |||||
Location | From | Numeric [o’clock] | |||
To | Numeric [o’clock] | ||||
Local invasion | Type |
| |||
| |||||
Anal sphincter complex involvement (detail visible only if “Yes”) | Notes | ||||
Sphincter invasion thickness |
| ||||
Height sphincter invasion |
| ||||
CRM Involvement | |||||
The shortest distance between the outermost part of the rectal tumor and the MRF | Numeric [mm]
| ||||
Margins | Type (multiple choice) |
| |||
Minimum distance localization | Type |
| |||
Type | |||||
Relationship with anterior peritoneal reflection | Type |
| |||
LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESOCT ADIPOSE TISSUE | |||||
Numeric | |||||
Lymph node metastases | Degree of suspicion |
| |||
Lymph node metastases (detail visible only if number > 0) | Location |
| |||
Lymph node metastases (detail visible only if “short axis diameter < 9 mm”) | Morphologic suspicious criteria |
| |||
Tumor deposits into mesorectal space (detail visible only if “Yes”) | Notes | ||||
Yes/No | |||||
Numeric | |||||
Extramural vascular invasion | Notes | ||||
Yes/No | |||||
Positive lymph nodes with extracapsular extension | Yes/No | ||||
Numeric | |||||
Notes | |||||
Notes | |||||
CONCLUSION | |||||
Diagnosis | cT, N, M, Stage (TNM classification, 8th Edition, AJCC-UICC 2017) | Tx T0 Tis T1 T2 T3 T4 | Diagnosis | cT, N, M, Stage (TNM, 8th Edition classification, AJCC-UICC 2017) | Tx T0 Tis T1 T2 T3 T4 |
Annotations and comments |
Appendix C.5. Images
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Significant key images | Images |
Appendix D
Appendix D.1. Patient Clinical Data
FIELD | DETAIL | NOTES/ALLOWED VALUES | |
ANTHROPOMETRIC DATA | |||
Weight | Numeric [Kg] | ||
Height | Numeric [cm] | ||
BMI | Numeric [calculated automatically] | ||
BSA | Numeric [calculated automatically] | ||
Age | Numeric | ||
age class |
| ||
PERSONAL RATINGS | |||
Family History for colorectal cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Family History for cancer (detail visible only if “Yes” and repeatable) | Yes/No | ||
Kind of relationship |
| ||
Notes | |||
Personal background for other malignancies | Yes/No | ||
Notes | |||
Hereditary genetic alterations (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Predisposing pathologies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Notes | |||
Risk factors (detail visible only if “Yes” and repeatable) | Smoke | Yes/No | |
SMOKER DETAILS (visible only if indicated Smoker = yes) | |||
Smoker (visible only if indicated Smoker) |
| ||
Cigarette smoker | Yes/No | ||
Number of cigarettes per day [if current smoker] |
| ||
Years of smoking | Numeric | ||
Number of years of cessation [if ex-smoker] |
| ||
pack-year [if ex-smoker or current smoker] | Numeric [calculated automatically] (No. of cigarettes per day × smoke years/20) | ||
Electronic cigarette | Yes/No | ||
Number of refills per day [if electronic cigarette = yes] | Numeric | ||
Number of years [if electronic cigarette = yes] | Numeric | ||
Notes | |||
High alcohol intake | Yes (more than 1 glass per day, if female, more than a 2 glasses per day, if male) No | ||
High meat intake | Yes (eats red or white meat more than 3 times a week [including raw ham, cooked ham, bresaola]) No | ||
High intake of salami | Yes (eats cured meats more than once a week [salami, mortadella, sausage, frankfurters …]) No | ||
Poor vegetable intake | Yes (less than 2 times per day) No (1 serving is considered as a salad plate [at least 50 g] or half a plate of cooked/raw vegetables or a glass of juice/centrifuge) | ||
Poor fruit intake | Yes (less than 3 whole fruits per day) No (1 whole fruit, such as apple, pear or orange, or 2/3 small fruits, such as apricots plums or fruit salad bowl) | ||
Notes | |||
Microsatellite instability | Yes/No | ||
Notes | |||
ALLERGIES AND ADVERSE REACTIONS | |||
Allergies (detail visible only if “Yes” and repeatable) | Yes/No | ||
Type |
| ||
Active substance/molecule [if drug or MDC allergy] | |||
Commercial name [if drug or MDC allergy] | |||
Notes | |||
PREVIOUS adverse reactions (detail visible only if “Yes” and repeatable) | Yes/No | ||
Date | Month/year [mm/yyyy] | ||
Description | |||
Grade |
| ||
Timing |
| ||
Notes |
Appendix D.2. Clinical Evaluation
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Clinical Data | ||
Previous examination (detail visible only if “Yes” and repeatable) | Yes/No | |
Type |
| |
Date | ||
Notes | ||
Rectal exploration performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Trans-rectal ultrasound performed (detail visible only if “Yes”) | Yes/No | |
Affected side |
| |
Distance to anal verge | Numeric [cm] | |
Distance to anorectal junction | Numeric [cm] | |
Sphincter involvement | Yes/No | |
Notes | ||
Histological examination of biopsy | Yes/No | |
Notes | ||
CEA dosage | Numeric | |
Blood exam completed | Numeric | |
Creatinine | Numeric | |
Liver function |
|
Appendix D.3. Exam Technique
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Examination Data | ||
Examination date | ||
Clinical indication | Post neoadjuvant treatment | |
Timing of Re-assessment | weeks | |
Sequences |
| |
MDC | ||
MDC (detail visible only if “Yes”) | Yes/No | |
Active principle | ||
Commercial name | ||
Dosage | Numeric [mL] | |
Flow rate | Numeric [mL/s] | |
Concentration | Numeric [mg I/mL] | |
Notes | ||
Premedication for allergy | Yes/No | |
Notes | ||
Preventive hydration for kidney failure | Yes/No | |
Notes | ||
Creatinine | ||
GFR (Glomerular Filtration Rate) | Numeric [mL/min] GFR = 141 × min (serum creatinine/kappa, 1) alpha × max (serum creatinine/kappa, 1) − 1.209 × 0.993Age × Gender × Race https://www.merckmanuals.com/medical-calculators/GFR_CKD_EPI-it.htm, accessed on 21 January 2021 | |
ADVERSE EVENTS | ||
Ongoing adverse events (detail visible only if “Yes”) | Yes/No | |
Date and event time | ||
Grade |
| |
Timing |
| |
Type | ALLERGIC/ALLERGIC-LIKE mild
Mild
| |
Treatment type |
| |
Event resolution |
| |
Notes |
Appendix D.4. Report
FIELD | DETAIL | NOTES/ALLOWED VALUES | |||
Tumor Staging | |||||
Remaining tumor |
| ||||
Notes | |||||
MRI Tumor Regression Grade (TRG) Dworak |
| ||||
Restricted Diffusion appearance |
| ||||
Mucin Response |
| ||||
Healthy rectal wall appearance |
| ||||
ycT-stage |
| ||||
Notes | |||||
Distance from the inferior border of the tumor to the anal verge | Numeric [cm] | ||||
Distance from the inferior border of the tumor to the anorectal junction | Numeric [cm] | ||||
Craniocaudal tumor length | Numeric [cm] | ||||
Anal sphincter complex involvement (detail visible only if “Yes”) | Yes/No | ||||
Type (multiple choice) |
| ||||
Localitation |
| ||||
CRM Involvement | |||||
The shortest distance between the outermost part of the rectal tumor and the MRF | Numeric [mm] | ||||
Margins |
| ||||
Localitation | Type (multiple choice) |
| |||
O-clock position | |||||
Relationship with anterior peritoneal reflection | Type |
| |||
LYMPH NODES AND TUMOR DEPOSITS: LOCAL METASTATIC DIFFUSION WITHIN MESOCT ADIPOSE TISSUE | |||||
Lymph node metastases (detail visible only if “Yes”) | Yes/No | ||||
Type |
| ||||
Number of suspected residual mesorectal lymph nodes (≥5 mm) | Numeric | ||||
Number of suspected extra mesorectal lymph nodes (≥5 mm) | Numeric | ||||
Tumor deposits into mesorectal space (detail visible only if “Yes”) | Notes | ||||
Yes/No | |||||
Numeric | |||||
Extramural vascular invasion | Notes | ||||
Yes/No | |||||
CONCLUSION | |||||
Diagnosis | cT, N, M, Stage (TNM classification, 8th Edition, AJCC-UICC 2017) | TX T0 Tis T1 T2 T3 T4 | NX N0 N1 N1a N1b N1c | MX M0 M1 | Stage 0 Stage I Stage IIa Stage IIb Stage IIIa Stage IIIb Stage IIIc Stage IV |
Annotations and comments | MRI response to treatment assessment |
|
Appendix D.5. Images
FIELD | DETAIL | NOTES/ALLOWED VALUES |
Significant key images | Images |
References
- Gunderman, R.B.; McNeive, L.R. Is structured reporting the answer? Radiology 2014, 273, 7–9. [Google Scholar] [CrossRef] [PubMed]
- (ESR) ESoR. Good practice for radiological reporting. Guidelines from the European Society of Radiology (ESR). Insights Imaging 2011, 2, 93–96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morgan, T.A.; Helibrun, M.E.; Kahn, C.E. Reporting initiative of the Radiological Society of North America: Progress and new directions. Radiology 2014, 273, 642–645. [Google Scholar] [CrossRef]
- Dunnick, N.R.; Langlotz, C.P. The radiology report of the future: A summary of the 2007 Intersociety Conference. J. Am. Coll. Radiol. 2008, 5, 626–629. [Google Scholar] [CrossRef]
- Ernst, B.P.; Hodeib, M.; Strieth, S.; Künzel, J.; Bischof, F.; Hackenberg, B.; Huppertz, T.; Weber, V.; Bahr, K.; Eckrich, J.; et al. Structured reporting of head and neck ultrasound examinations. BMC Med. Imaging 2019, 19, 25. [Google Scholar] [CrossRef] [PubMed]
- Brown, P.J.; on behalf of the YCR BCIP Study Group; Rossington, H.; Taylor, J.; Lambregts, D.M.J.; Morris, E.; West, N.P.; Quirke, P.; Tolan, D. Standardised reports with a template format are superior to free text reports: The case for rectal cancer reporting in clinical practice. Eur. Radiol. 2019, 29, 5121–5128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinto Dos Santos, D.; Baeßler, B. Big data, artificial intelligence, and structured reporting. Eur. Radiol. Exp. 2018, 2, 42. [Google Scholar] [CrossRef] [Green Version]
- Beets-Tan, R.G.H.; Lambregts, D.M.J.; Maas, M.; Bipat, S.; Barbaro, B.; Curvo-Semedo, L.; Fenlon, H.M.; Gollub, M.J.; Gourtsoyianni, S.; Halligan, S.; et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur. Radiol. 2018, 28, 1465–1475. [Google Scholar] [CrossRef] [Green Version]
- Gollub, M.J.; Arya, S.; Beets-Tan, R.G.; DePrisco, G.; Gonen, M.; Jhaveri, K.; Kassam, Z.; Kaur, H.; Kim, D.; Knezevic, A.; et al. Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. Abdom. Radiol. 2018, 43, 2893–2902. [Google Scholar] [CrossRef]
- Horvat, N.; Carlos Tavares Rocha, C.; Clemente Oliveira, B.; Petkovska, I.; Gollub, M.J. MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management. Radiographics 2019, 39, 367–387. [Google Scholar] [CrossRef]
- Jia, X.X.; Wang, Y.; Cheng, J.; Yao, X.; Yin, M.-J.; Zhou, J.; Ye, Y.-J. Low-Versus High-Risk Rectal cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy. AJR Am. J. Roentgenol. 2018, 211, 327–334. [Google Scholar] [CrossRef] [PubMed]
- Taylor, F.G.; Quirke, P.; Heald, R.J.; Moran, B.; Blomqvist, L.; Swift, I.; Sebag-Montefiore, D.J.; Tekkis, P.; Brown, G. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: A prospective, multicenter, European study. Ann. Surg. 2011, 253, 711–719. [Google Scholar] [CrossRef]
- Giannini, V.; Mazzetti, S.; Bertotto, I.; Chiarenza, C.; Cauda, S.; Delmastro, E.; Bracco, C.; Di Dia, A.; Leone, F.; Medico, E.; et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 878–888. [Google Scholar] [CrossRef] [PubMed]
- Ciolina, M.; Caruso, D.; De Santis, D.; Zerunian, M.; Rengo, M.; Alfieri, N.; Musio, D.; De Felice, F.; Ciardi, A.; Tombolini, V.; et al. Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer: Role of perfusion parameters in the assessment of response to treatment. Radiol. Med. 2019, 124, 331–338. [Google Scholar] [CrossRef] [PubMed]
- The Updated Version of the AIOM Guidelines. Available online: https://www.aiom.it/linee-guida-aiom/ (accessed on 21 January 2021).
- Weiser, M.R. AJCC 8th Edition: Colorectal Cancer. Ann. Surg. Oncol. 2018, 25, 1454–1455. [Google Scholar] [CrossRef] [Green Version]
- Dalkey, N.; Helmer, O. An Experimental Application of the DELPHI Method to the Use of Experts. 1963. Available online: https://www.rand.org/content/dam/rand/pubs/research_memoranda/2009/RM727.1.pdf (accessed on 21 January 2021).
- Kahn, C.E.; Genereaux, B.; Langlotz, C.P. Conversion of Radiology Reporting Templates to the MRRT Standard. J. Digit. Imaging 2015, 28, 528–536. [Google Scholar] [CrossRef] [Green Version]
- Becker, G. Creating comparability among reliability coefficients: The case of Cronbach alpha and Cohen kappa. Psychol. Rep. 2000, 87, 1171–1182. [Google Scholar] [CrossRef]
- Cronbach, L.J. Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16, 297–334. [Google Scholar] [CrossRef] [Green Version]
- (ESR) ESoR. ESR paper on structured reporting in radiology. Insights Imaging 2018, 9, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Chen, J.Y.; Sippel Schmidt, T.M.; Carr, C.D.; Kahn, C.E. Enabling the Next-Generation Radiology Report: Description of Two New System Standards. Radiographics 2017, 37, 2106–2112. [Google Scholar] [CrossRef] [Green Version]
- Cusumano, D.; Meijer, G.; Lenkowicz, J.; Chiloiro, G.; Boldrini, L.; Masciocchi, C.; Dinapoli, N.; Gatta, R.; Casà, C.; Damiani, A.; et al. A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer. Radiol. Med. 2021, 126, 421–429. [Google Scholar] [CrossRef]
- Crimì, F.; Capelli, G.; Spolverato, G.; Bao, Q.R.; Florio, A.; Rossi, S.M.; Cecchin, D.; Albertoni, L.; Campi, C.; Pucciarelli, S.; et al. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC). Radiol. Med. 2020, 125, 1216–1224. [Google Scholar] [CrossRef] [PubMed]
- Cusumano, D.; Dinapoli, N.; Boldrini, L.; Chiloiro, G.; Gatta, R.; Masciocchi, C.; Lenkowicz, J.; Casà, C.; Damiani, A.; Azario, L.; et al. Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer. Radiol. Med. 2018, 123, 286–295. [Google Scholar] [CrossRef]
- Horvat, N.; Veeraraghavan, H.; Pelossof, R.A.; Fernandes, M.C.; Arora, A.; Khan, M.; Marco, M.; Cheng, C.-T.; Gonen, M.; Pernicka, J.S.G.; et al. Radiogenomics of rectal adenocarcinoma in the era of precision medicine: A pilot study of associations between qualitative and quantitative MRI imaging features and genetic mutations. Eur. J. Radiol. 2019, 113, 174–181. [Google Scholar] [CrossRef] [PubMed]
- Caruso, D.; Zerunian, M.; Ciolina, M.; de Santis, D.; Rengo, M.; Soomro, M.H.; Giunta, G.; Conforto, S.; Schmid, M.; Neri, E.; et al. Haralick’s texture features for the prediction of response to therapy in colorectal cancer: A preliminary study. Radiol. Med. 2018, 123, 161–167. [Google Scholar] [CrossRef]
- Fornell-Perez, R.; Vivas-Escalona, V.; Aranda-Sanchez, J.; Gonzalez-Dominguez, M.C.; Rubio-Garcia, J.; Aleman-Flores, P.; Lozano-Rodriguez, A.; Porcel-de-Peralta, G.; Loro-Ferrer, J.F. Primary and post-chemoradiotherapy MRI detection of extramural venous invasion in rectal cancer: The role of diffusion-weighted imaging. Radiol. Med. 2020, 125, 522–530. [Google Scholar] [CrossRef] [PubMed]
- De Cecco, C.N.; Ciolina, M.; Caruso, D.; Rengo, M.; Ganeshan, B.; Meinel, F.G.; Musio, D.; De Felice, F.; Tombolini, V.; Laghi, A. Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: Initial experience. Abdom. Radiol. 2016, 41, 1728–1735. [Google Scholar] [CrossRef] [PubMed]
- Caruso, D.; Zerunian, M.; De Santis, D.; Biondi, T.; Paolantonio, P.; Rengo, M.; Bellini, D.; Ferrari, R.; Ciolina, M.; Lucertini, E.; et al. Magnetic Resonance of Rectal cancer Response to Therapy: An Image Quality Comparison between 3.0 and 1.5 Tesla. Biomed Res. Int. 2020, 2020, 9842732. [Google Scholar] [CrossRef]
- Schwartz, L.H.; Panicek, D.M.; Berk, A.R.; Li, Y.; Hricak, H. Improving communication of diagnostic radiology findings through structured reporting. Radiology 2011, 260, 174–181. [Google Scholar] [CrossRef] [Green Version]
- Marcovici, P.A.; Taylor, G.A. Journal Club: Structured radiology reports are more complete and more effective than unstructured reports. AJR Am. J. Roentgenol. 2014, 203, 1265–1271. [Google Scholar] [CrossRef]
- Ernst, B.P.; Strieth, S.; Katzer, F.; Hodeib, M.; Eckrich, J.; Bahr, K.; Rader, T.; Künzel, J.; Froelich, M.F.; Matthias, C.; et al. The use of structured reporting of head and neck ultrasound ensures time-efficiency and report quality during residency. Eur. Arch. Otorhinolaryngol. 2020, 277, 269–276. [Google Scholar] [CrossRef] [PubMed]
- Goldberg-Stein, S.; Chernyak, V. Adding Value in Radiology Reporting. J. Am. Coll. Radiol. 2019, 16, 1292–1298. [Google Scholar] [CrossRef] [PubMed]
- Brady, A.P. Radiology reporting-from Hemingway to HAL? Insights Imaging 2018, 9, 237–246. [Google Scholar] [CrossRef] [Green Version]
- Weiss, D.L.; Langlotz, C.P. Structured reporting: Patient care enhancement or productivity nightmare? Radiology 2008, 249, 739–747. [Google Scholar] [CrossRef] [PubMed]
- Faggioni, L.; Coppola, F.; Ferrari, R.; Neri, E.; Regge, D. Usage of structured reporting in radiological practice: Results from an Italian online survey. Eur. Radiol. 2017, 27, 1934–1943. [Google Scholar] [CrossRef] [PubMed]
Panelist (P#) | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | Sum of Scores |
---|---|---|---|---|---|---|---|---|---|---|
Patient clinical data | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 2 | 4 | 31 |
Clinical evaluation | 4 | 4 | 3 | 4 | 4 | 4 | 3 | 3 | 4 | 33 |
Exam technique | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 35 |
Report | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 35 |
Conclusion | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 35 |
SR | Statistic Value | SR Section | ||||
---|---|---|---|---|---|---|
Patient Clinical Data | Clinical Evaluation | Exam Technique | Report | Conclusion | ||
Staging | Mean value | 3.4 | 3.7 | 3.9 | 3.9 | 3.9 |
Minimum value | 2.0 | 3.0 | 3.0 | 3.0 | 3.0 | |
Maximum value | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | |
Restaging | Mean value | 3.4 | 3.5 | 3.9 | 3.9 | 3.9 |
Minimum value | 2.0 | 2.0 | 3.0 | 3.0 | 3.0 | |
Maximum value | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 |
Panelist (P#) | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | Sum of Scores |
---|---|---|---|---|---|---|---|---|---|
Patient clinical data | 4 | 4 | 2 | 4 | 4 | 4 | 3 | 2 | 27 |
Clinical evaluation | 4 | 4 | 3 | 4 | 4 | 4 | 3 | 3 | 28 |
Exam technique | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 31 |
Report | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 31 |
Conclusion | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 31 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Granata, V.; Caruso, D.; Grassi, R.; Cappabianca, S.; Reginelli, A.; Rizzati, R.; Masselli, G.; Golfieri, R.; Rengo, M.; Regge, D.; et al. Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal. Cancers 2021, 13, 2135. https://doi.org/10.3390/cancers13092135
Granata V, Caruso D, Grassi R, Cappabianca S, Reginelli A, Rizzati R, Masselli G, Golfieri R, Rengo M, Regge D, et al. Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal. Cancers. 2021; 13(9):2135. https://doi.org/10.3390/cancers13092135
Chicago/Turabian StyleGranata, Vincenza, Damiano Caruso, Roberto Grassi, Salvatore Cappabianca, Alfonso Reginelli, Roberto Rizzati, Gabriele Masselli, Rita Golfieri, Marco Rengo, Daniele Regge, and et al. 2021. "Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal" Cancers 13, no. 9: 2135. https://doi.org/10.3390/cancers13092135
APA StyleGranata, V., Caruso, D., Grassi, R., Cappabianca, S., Reginelli, A., Rizzati, R., Masselli, G., Golfieri, R., Rengo, M., Regge, D., Lo Re, G., Pradella, S., Fusco, R., Faggioni, L., Laghi, A., Miele, V., Neri, E., & Coppola, F. (2021). Structured Reporting of Rectal Cancer Staging and Restaging: A Consensus Proposal. Cancers, 13(9), 2135. https://doi.org/10.3390/cancers13092135